Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Compumedics Limited ( (AU:CMP) ) has issued an announcement.
Compumedics Limited reported record sales orders of $63.4 million, marking a 22% increase, and revenue of $51 million, up 15% from the previous year. The company has achieved significant growth in its Somfit SaaS platform, securing a $10 million U.S. pipeline and forming strategic partnerships with major pharmaceutical companies. With FDA clearance for its products and expansion into new markets, Compumedics is positioned for continued growth in FY26, projecting revenues over $70 million.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited operates in the medical technology industry, focusing on sleep diagnostics and brain monitoring solutions. The company offers products such as Somfit, a sleep monitoring SaaS platform, and OrionMEG, a brain imaging system, with a strong market presence in the U.S. and expansion plans in China.
Average Trading Volume: 112,290
Technical Sentiment Signal: Buy
Current Market Cap: A$57.67M
See more data about CMP stock on TipRanks’ Stock Analysis page.